BioNTech, or Biopharmaceutical New Technologies, is one of the leading pharmaceutical companies that are developing and manufacturing active immunotherapies for treating a variety of diseases. BioNTech stock price particularly started surging in late March 2021, followed by another extreme price jump in mid-July. This second surge took it to an all-time high at $390 on August 6th.
While the price has corrected since then, many are still extremely interested in the company, which is why we decided to create this guide on how to buy BioNTech stock and make it as simple as possible for everyone interested in investing.
5 Providers that match your filters
Cost per trade
Fees per trade
67% of retail investor accounts lose money when trading CFDs with this provider.
78.77% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider.
83% of retail investor accounts lose money when trading CFDs with this provider.
There is no guarantee you will make money with this provider. Your capital is at risk.
AvaTrade is a great option, if you want to trade forex, CFDs, and popular cryptos with competitively low spreads and no commissions then . Clients have unfettered access to a demo account as well as the MT4 and MT5 series of platforms.
In This Guide
The best place to go if you wish to buy BioNTech stock is eToro — a popular broker that offers access to a variety of assets available to investors, alongside numerous features and perks that its users regularly enjoy. To do it yourself, all you need to do is follow these few steps:
67% of retail investor accounts lose money when trading CFDs with this provider.
If you wish to buy BioNTech stocks, the first step you need to make is to get a good broker. Of course, there are plenty of brokers available, so choosing the right one can be a challenge. After extensive research, we have come up with two excellent solutions worthy of consideration.
eToro is one of the most popular stockbrokers in the world, which is not surprising since it is also one of the best ones. It has more than 20 million individual users in 2021, which is more than enough to confirm the quality of its service.
The platform offers high levels of security, and it is well-known for being safe, reliable, and fully licensed and regulated by multiple regulatory bodies. Some of them include CySEC, FINRA, UK FCA, and ASIC, among others.
eToro’s platform offers more than 2,500 investments instrument, and it is entirely commission-free, which is another thing that attracts investors and traders in such great numbers. It is also well-known for its social trading feature, which allows users to copy others and gain insight from professional traders, thus learning as they go and still making profits along the way. With a positive experience so early in their trading careers, they are more likely to stick around and continue improving.
Finally, the company also offers a CopyPortfolio feature, which is an easy way to invest in entire pre-prepared portfolios, filled with assets that are considered to be the most profitable, or the safest to invest in. And, as mentioned, the platform allows you to start trading with a low minimum deposit of only $50.
As an alternative to eToro, we can suggest Capital.com — a UK-based broker that is regulated and licensed by the FCA, but also CySEC. This is another major broker, although it is still significantly smaller than eToro itself. The platform has around 360,000 traders, many of which like using it due to its lack of fees on buying, selling, deposits, and withdrawals.
The platform’s available asset count is even greater than what you can find on eToro, with access to over 3,000 global stock markets. And, of course, BioNTech stock is among them.
The platform also allows you to trade CFDs, engage in margin trading, and do so much more, all while using its top-notch and easy-to-use trading platform. It also features a large and thorough knowledge base, filled with guides, educational materials, and even online courses that can help traders learn more about the world of trading, and find their way through it.
And, it should be noted that the minimum deposit for the platform is only £20, which makes it affordable to pretty much anyone who has plans to start trading.
Obviously, you need to do your research before investing, stock trades, or anything, as not doing so is a sure way to lose your money. Most assets can be unpredictable, and while stocks are nowhere near as volatile as crypto like Bitcoin, they are not completely still, either.
With that said, you need to arm yourself with the knowledge that will let you know what to expect, what BioNTech products to keep an eye on, how certain events and developments may impact the BioNTech stock price, and alike.
The first thing to do before you buy BioNTech stock is to research who and what the company is, in the first place. As mentioned earlier, the firm has seen a rapid price surge as it worked on developing a COVID-19 vaccine, which is no coincidence, as the world is desperate to shake off the pandemic that has been plaguing it for over a year and a half now.
BioNTech stock has been listed on Nasdaq for the last two years, since October 11th, 2019. In that time, the stock price has had its ups and downs, but by looking at its overall price-performance — it has constantly been on the rise.
Of course, the price did engage in corrections and recoveries overtime, but overall, the firm has been riding the bullish trend since its stock was listed. Its harshest drop was seen between September 17th and October 1st of 2021, although it is worth noting that it came after a particularly sudden rally that took it from $217 on July 9th to its current all-time high at $447, which it reached on August 9th. In a single month, the company more than doubled the value of its stock.
So, when the price corrected to $375 a few days later, that was not particularly surprising. People may have been caught off guard, however, when its price sank through the support level at $350 to the next one at $240, although the price has already started to recover and grow anew since then. So, seeing as it is now quite near to its bottom, sitting at exactly $250 as of October 15th, 2021 — it might be a perfect time to start investing in it in the near future.
BioNTech reported that 2020 was a rather transformational year for the company, with the development and approval of the first mRNA drug in history. As of March 2021, the company delivered over 200 million doses of its Pfizer-BioNTech vaccine to over 65 countries
The company also saw a massive increase in revenue in the final quarter of 2020, earning an estimated €345.4 million. To put this into perspective, the firm earned only $28 million during the last quarter of 2019. Total revenue for 2019 was €108.6 million, while in 2020, that figure exceeded €482.3 million.
The increase in total revenue came due to two collaboration agreements for developing a COVID-19 vaccine, which ultimately led to the recognition of COVID-19 vaccine commercial revenues.
In the first quarter of 2021, the company recorded sales of €2.05 billion, with more than half of the amount flowing to its bottom line.
Dividend stocks are often pursued by investors as they provide passive income, allowing investors to earn without having to do anything but buy and own stocks for a prolonged period of time. Of course, it is worth noting that very few biotechs offer dividends, as most of them do not see high enough cash flow in order to even consider, much less sustain a dividend program.
However, when it comes to BioNTech, the company actually had a shareholder meeting during which its CFO, Sierk Poetting, disclosed that the management board and supervisory board will evaluate the possibility of proposing the initiation of a dividend next year. So, while there are no dividends to speak of right now, this might change at some point in 2022.
When institutional investors go for a company, they typically research every aspect of it, including the ESG rating of the firm. ESG (Environmental, Social, Governance) ranking shows them whether or not a company should even be taken into consideration for investing.
Earlier this year, BioNTech was awarded a “Prime” rating in its very first ESG rating, by the rating agency ISS ESG. As such, the company actually managed to enter a list of the top 10% of all rated companies in the Biotechnology and Pharmaceutical sector, which is actually quite encouraging for anyone looking to invest in it.
When it comes to price forecasts of any asset, including stocks, they can vary quite greatly from one technical analysis to the next. In other words, it depends on who you ask. With that said, BioNTech stock forecast has seen a number of analysts from Wall Street predicting that its value could return to around $314.57 and remain there by October 7th, 2022.
All forecasts should be taken with a grain of salt, of course, as there is no way for anyone to know the future, and there are many things like dividend yields, market caps, p/e ratio, eps, etc., that could go right or wrong, and severely impact the BioNTech stock price. But, for the time being, experts appear to be optimistic, which is yet another reason to consider investing in this company.
Back in 2020, under the healthcare threat of COVID-19, BioNTech announced that it will be partnering with Pfizer (PFE) for developing the vaccine for the prevention of the coronavirus. While many know this vaccine as “the Pfizer vaccine,” and BioNTech is usually completely left out, the company’s contribution is undeniable and priceless. Together, the two firms created a vaccine that offers a 95% efficiency in preventing infectious disease, and this level of protection is confirmed at least 7 days after the second dose is received.
This very vaccine was also the first mRNA vaccine ever to be authorized in the UK. Only days later, it was approved in the United States, as well as Canada and Switzerland, with other countries soon to follow.
The vaccine’s official name is BNT162b2, it requires 2 shots that are 21 days apart, and it is recommended that moderately to severely immunocompromised people receive the 3rd dose, at least 28 days after the second one. Others can also receive the booster dose, although it is recommended that they wait at least six months following the 2nd shot.
Finally, investors should gather all the market data they have found and assess whether or not the stock is a good buy or not. In the case of BioNTech stock, the results weigh heavily towards the positive conclusion. The company has had a very strong and highly bullish price behavior, it was awarded a Prime ESG rating, and it has seen enough money to start considering issuing dividends.
Furthermore, the COVID-10 booster shots could also have a positive impact on the stock price, and it is worth remembering, once again, that the company’s vaccine is the first mRNA vaccine to be approved throughout the world. Of course, it is also worth noting that the firm might see some trouble due to competition, just like other vaccine producers, especial after another pharmaceutical competitor, Merck, announced a very promising antiviral COVID-19 pill, which appears to be reducing hospitalization in unvaccinated patients who are found to be COVID-positive.
The safety of the pill is still a matter of debate, but if it should be proven safe, it is likely that many would simply switch to pills in case of catching the virus, rather than go for the vaccines like Pfizer-BioNTech, Moderna, Astrazeneca, etc., which have already caused a lot of controversy in the world due to the people’s suspicion and fear of the disease.
With that out of the way, we have also prepared a step-by-step guide for opening an account on eToro and investing in BioNTech stocks.
The first step is to go to eToro’s website and create an account. Doing so is a quick and simple process that you can complete manually, or sign up with Facebook or Google accounts.
The next step is to go through the KYC procedure, which means that you will have to provide an official, government-issued document that proves that you are who you say you are. eToro allows you to do this by uploading a copy of your passport or driver’s license, as well as a utility bill or bank account statement that is not more than three months old.
After verifying your account, you will be free to deposit money and then proceed to trading. Money can be deposited on eToro by using:
Finally, you are ready to buy BioNTech stocks. Simply type “BioNTech” or BNTX into the search field at the top of the platform, and you will easily find it. After that, click the big, blue “Trade” button, fill in the details such as the amount you wish to buy, and enter a trade.z
So, with everything that we have seen, it is clear that BioNTech is doing a lot of things right, and that there is a huge potential lying with this company. Analysts are also quite optimistic about its future, predicting that the stock’s price will increase and once again reach the lower $300s.
It is also worth noting that a lot of the company’s success will depend on the demand for the so-called Pfizer vaccine, which BioNTech helped develop, as well as the future success of the new pills meant to be used for treating the disease.
There is grand potential in investing into BioNTech stocks, but also risk. With that in mind, each investor will have to decide for themselves whether they believe that buying is the right move to make, or if it is better to sell. And, of course, always remember not to risk the money you can’t afford to lose.
BioNTechis a German biotechnology firm that develops and manufactures immunological therapies for patient-specific approaches to the treatment of diseases. It is also a company that collaborated with Pfizer on the creation of the vaccine known as BNT162b2.
BioNTech owners are predominantly mutual funds and other institutional stakeholders, with even the largest shareholder owning less than 1% of the company.
BioNTech is based in Mainz, Germany, although it also has research locations in San Diego and Cambridge, while it also owns production facilities in Idar-Oberstein, Martinsried, Neuried, and Berlin.
At the time of writing (October 15th), the company’s stock is valued at $250.33.
Currently, there are more analysts who suggest that the stock is worth investing in at this time than those who oppose it.
The best way to purchase BioNTech stock is to do it on eToro’s platform, which offers 100% commission-free purchases.
Ali is an experienced writer covering the cryptocurrency markets and the blockchain industry. He has 8 years of experience writing about cryptocurrencies, technology, and trading. His work can be found in various high-profiled investment sites including CCN, Capital.com, BeInCrypto, Bitcoinist, and NewsBTC.
Best UK Stock, Forex, CFD, Crypto, Social or Day Trading Platform that meets your needs.